NASDAQ : APRE
Aprea Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.4846 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Aprea Therapeutics, Inc. (APRE) reported revenue of 5.18K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 5.18K | 285.76K | 1.50M | 583.23K | ||
| Cost of Revenue | 6.72M | 7.04M | 9.36M | 7.63M | 16.40M | 23.90M |
| Gross Profit | -6.72M | -6.76M | -7.86M | -7.04M | -16.40M | -23.90M |
| Selling, General & Admin | 6.51M | 6.48M | 6.46M | 8.43M | 20.97M | 13.55M |
| Operating Expenses | 6.51M | 6.48M | 6.46M | 8.43M | 20.97M | 13.55M |
| Operating Income | -13.22M | -13.23M | -14.32M | -15.47M | -37.37M | -37.45M |
| Interest & Investment Income | 763.04K | 652.09K | 1.29M | 1.22M | 448.67K | 1.65K |
| Currency Exchange Gain (Loss) | -3.73K | -95.32K | 71.80K | -38.93K | 281.53K | 317.40K |
| Other Non Operating Income (Expenses) | 156.50K | 77.50K | ||||
| EBT Excluding Unusual Items | -12.31M | -12.60M | -12.96M | -14.29M | -36.64M | -37.13M |
| Pretax Income | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -37.13M |
| Net Income | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -37.13M |
| Net Income to Common | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -37.13M |
| Shares Outstanding (Basic) | 20.62M | 6.54M | 5.51M | 3.62M | 1.66M | 1.06M |
| Shares Outstanding (Diluted) | 20.62M | 6.54M | 5.51M | 3.62M | 1.66M | 1.06M |
| EPS (Basic) | -0.60 | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 |
| EPS (Diluted) | -0.60 | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 |
| Free Cash Flow | -12.18M | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Free Cash Flow Per Share | -0.59 | -1.97 | -2.46 | -3.39 | -15.09 | -35.41 |
| Operating Margin | -255,025.52% | -4,631.12% | -953.00% | -2,652.80% | ||
| Profit Margin | -237,362.80% | -4,409.16% | -862.43% | -2,449.59% | ||
| Free Cash Flow Margin | -234,974.18% | -4,512.35% | -903.26% | -2,103.92% | ||
| EBITDA | -13.20M | -13.21M | -14.30M | -15.46M | -37.37M | -37.43M |
| D&A For EBITDA | 22.03K | 21.71K | 22.32K | 7.05K | 4.40K | 12.83K |
| EBIT | -13.22M | -13.23M | -14.32M | -15.47M | -37.37M | -37.45M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 41.23M | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Cash & Short-Term Investments | 41.23M | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Prepaid Expenses | 679.69K | 961.90K | 726.25K | 914.27K | 1.37M | 3.51M |
| Total Current Assets | 41.91M | 15.56M | 23.58M | 22.52M | 30.15M | 56.58M |
| Property, Plant & Equipment | 64.03K | 59.81K | 81.52K | 88.36K | 2.32K | 209.68K |
| Other Long-Term Assets | 312.78K | 312.35K | 321.83K | 40.72K | 29.37K | |
| Total Assets | 42.29M | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Accounts Payable | 935.14K | 713.67K | 1.35M | 1.67M | 842.75K | 1.77M |
| Accrued Expenses | 2.16M | 2.05M | 2.01M | 2.19M | 2.36M | 5.35M |
| Current Portion of Leases | 190.47K | |||||
| Current Unearned Revenue | 528.97K | |||||
| Total Current Liabilities | 3.09M | 2.76M | 3.36M | 4.39M | 3.20M | 7.32M |
| Total Liabilities | 3.09M | 2.76M | 3.36M | 4.39M | 3.20M | 7.32M |
| Common Stock | 12.39K | 8.19K | 5.48K | 3.74K | 2.65K | 1.09K |
| Additional Paid-In Capital | 389.60M | 356.71M | 350.97M | 335.64M | 330.06M | 241.00M |
| Retained Earnings | -340.52M | -333.64M | -321.04M | -308.08M | -293.80M | -181.13M |
| Comprehensive Income & Other | -10.62M | -10.63M | -10.63M | -10.61M | -10.62M | -10.36M |
| Total Common Equity | 38.47M | 12.44M | 19.31M | 16.95M | 25.64M | 49.51M |
| Shareholders' Equity | 39.20M | 13.17M | 20.62M | 18.26M | 26.95M | 49.51M |
| Total Liabilities & Equity | 42.29M | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Total Debt | 190.47K | |||||
| Net Cash (Debt) | 41.23M | 14.60M | 22.85M | 21.61M | 28.79M | 52.89M |
| Net Cash Per Share | 2.00 | 2.23 | 4.15 | 5.97 | 17.37 | 49.69 |
| Filing Date Shares Outstanding | 12.59M | 11.45M | 5.49M | 5.43M | 3.73M | 1.06M |
| Total Common Shares Outstanding | 12.39M | 8.19M | 5.48M | 3.74M | 2.66M | 1.06M |
| Working Capital | 38.82M | 12.80M | 20.22M | 18.14M | 26.95M | 49.27M |
| Book Value Per Share | 3.10 | 1.52 | 3.52 | 4.54 | 9.66 | 45.97 |
| Tangible Book Value | 38.47M | 12.44M | 19.31M | 16.95M | 25.64M | 49.51M |
| Tangible Book Value Per Share | 3.10 | 1.52 | 3.52 | 4.54 | 9.66 | 45.97 |
| Machinery | 153.96K | 153.96K | 138.48K | 45.39K | 140.88K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -12.31M | -12.60M | -12.96M | -14.29M | -112.66M | -37.13M |
| Depreciation & Amortization | 22.03K | 21.71K | 22.32K | 7.05K | 186.44K | 271.68K |
| Asset Writedown & Restructuring Costs | 72.52M | |||||
| Stock-Based Compensation | 466.09K | 517.19K | 506.87K | 444.46K | 16.98M | 7.81M |
| Other Operating Activities | 3.73K | 95.32K | -71.80K | 38.93K | -281.53K | -317.40K |
| Change in Accounts Payable | -262.77K | -646.70K | -314.21K | 827.46K | -858.51K | -2.73M |
| Change in Unearned Revenue | -528.97K | 528.97K | ||||
| Change in Other Net Operating Assets | -89.83K | -282.39K | -212.22K | 262.27K | -900.07K | -5.60M |
| Operating Cash Flow | -12.17M | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Capital Expenditures | -15.40K | -15.48K | -93.09K | |||
| Investing Cash Flow | -15.40K | -15.48K | -93.09K | |||
| Issuance of Common Stock | 40.19M | 5.05M | 16.14M | 5.79M | 682.97K | 1.75M |
| Other Financing Activities | -3.30M | -407.46K | -1.32M | -648.93K | ||
| Financing Cash Flow | 36.89M | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
| Foreign Exchange Rate Adjustments | -370.00 | 4.68K | -7.18K | -8.40K | 38.76K | -2.47K |
| Net Cash Flow | 24.70M | -8.25M | 1.24M | -7.14M | -24.29M | -35.94M |
| Free Cash Flow | -12.18M | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Free Cash Flow Margin | -234,974.18% | -4,512.35% | -903.26% | -2,103.92% | ||
| Free Cash Flow Per Share | -0.59 | -1.97 | -2.46 | -3.39 | -15.09 | -35.41 |
| Levered Free Cash Flow | -8.15M | -8.56M | -9.27M | -7.67M | -7.97M | |
| Unlevered Free Cash Flow | -8.15M | -8.56M | -9.27M | -7.67M | -7.97M | |
| Change in Working Capital | -352.60K | -929.10K | -1.06M | 1.62M | -1.76M | -8.33M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 6.10M | 5.97M | 17.88M | 17.56M | 17.54M | |
| Enterprise Value | -35.13M | -7.02M | -7.06M | -6.48M | -12.46M | |
| Last Close Price | 0.48 | 0.85 | 3.29 | 4.70 | 6.62 | |
| PS Ratio | 1,176.79 | 20.88 | 11.90 | 30.11 | ||
| PB Ratio | 0.16 | 0.45 | 0.87 | 0.96 | 0.65 | |
| P/TBV Ratio | 0.16 | 0.48 | 0.93 | 1.04 | 0.68 | |
| Debt / Equity Ratio | 0.00 | |||||
| Net Debt / Equity Ratio | -1.05 | -1.11 | -1.11 | -1.18 | -1.07 | -1.07 |
| Net Debt / EBITDA Ratio | 3.12 | 1.10 | 1.60 | 1.40 | 0.77 | 1.41 |
| Net Debt / FCF Ratio | 3.38 | 1.13 | 1.68 | 1.76 | 1.15 | 1.40 |
| Asset Turnover | 0.00 | 0.01 | 0.06 | 0.02 | ||
| Quick Ratio | 13.33 | 5.28 | 6.80 | 4.93 | 8.99 | 7.25 |
| Current Ratio | 13.55 | 5.63 | 7.01 | 5.13 | 9.42 | 7.73 |
| Return on Equity (ROE) | -46.15% | -74.58% | -66.66% | -63.19% | -294.69% | |
| Return on Assets (ROA) | -27.73% | -41.45% | -38.39% | -36.62% | -53.71% | |
| Return on Capital Employed (ROCE) | -33.70% | -100.50% | -69.50% | -84.70% | -138.60% | -75.60% |
| Earnings Yield | -123.19% | -211.20% | -72.47% | -81.35% | -642.23% | |
| FCF Yield | -199.67% | -216.14% | -75.90% | -69.87% | -142.58% | |
| Buyback Yield / Dilution | -243.85% | -18.67% | -52.31% | -118.31% | -55.69% | -0.72% |